{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:00:48Z","timestamp":1794049248630,"version":"4.8.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"8048","license":[{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2025,1,30]]},"DOI":"10.1038\/s41586-024-08305-z","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T18:53:40Z","timestamp":1733943220000},"page":"1218-1227","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":141,"title":["Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours"],"prefix":"10.1038","volume":"637","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1360-348X","authenticated-orcid":false,"given":"Ignacio","family":"Melero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"de Miguel Luken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"de Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4412-7842","authenticated-orcid":false,"given":"Elena","family":"Garralda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Mart\u00edn-Liberal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Joerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guzman","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Elisabeth","family":"Goebeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2166-3394","authenticated-orcid":false,"given":"Martin","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2279-6906","authenticated-orcid":false,"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Reig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Esperanza","family":"Rodriguez Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4921-829X","authenticated-orcid":false,"given":"Emiliano","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2547-016X","authenticated-orcid":false,"given":"Jorge","family":"Esteban-Villarrubia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Oberoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1630-7453","authenticated-orcid":false,"given":"Paula","family":"Sabat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9630-4233","authenticated-orcid":false,"given":"Juan Jos\u00e9","family":"Soto-Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6549-8124","authenticated-orcid":false,"given":"Kira-Lee","family":"Koster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Saavedra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus","family":"Sayehli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1373-0840","authenticated-orcid":false,"given":"Tanja","family":"Gromke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"L\u00e4ubli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egle","family":"Ramelyte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Fortuny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9352-4329","authenticated-orcid":false,"given":"Ana","family":"Landa-Magdalena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5027-6388","authenticated-orcid":false,"given":"Irene","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9023-4529","authenticated-orcid":false,"given":"Javier","family":"Torres-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Hernando-Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabricio","family":"Racca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Richly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9568-8164","authenticated-orcid":false,"given":"Andreas M.","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Eggenschwiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Sanduzzi-Zamparelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4787-5176","authenticated-orcid":false,"given":"Anna","family":"Vilalta-Lacarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9414-378X","authenticated-orcid":false,"given":"J\u00f6rg","family":"Trojan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Galle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"Foerster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0636-7351","authenticated-orcid":false,"given":"Zlatko","family":"Trajanoski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4055-3841","authenticated-orcid":false,"given":"Hubert","family":"Hackl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9329-0294","authenticated-orcid":false,"given":"Falk","family":"Gogolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7828-3950","authenticated-orcid":false,"given":"Florestan J.","family":"Koll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Wild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix Kyoung Hwan","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0541-2365","authenticated-orcid":false,"given":"Matthias","family":"Machacek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"Gajewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1332-0973","authenticated-orcid":false,"given":"Wolf H.","family":"Fridman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M. M.","family":"Eggermont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1221-7421","authenticated-orcid":false,"given":"Ralf","family":"Bargou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Sch\u00f6niger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"R\u00fcschoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasiia","family":"Tereshchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Zink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix S.","family":"Lichtenegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Akdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"R\u00fcdiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"L\u2019Huillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aradhana","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3353-7919","authenticated-orcid":false,"given":"Markus","family":"Haake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Auckenthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0886-0841","authenticated-orcid":false,"given":"Ana","family":"Gjorgjioska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3347-4973","authenticated-orcid":false,"given":"Bernhard","family":"R\u00f6ssler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Liebig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Reichhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Schuberth-Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Wischhusen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Fettes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1770-413X","authenticated-orcid":false,"given":"Marlene","family":"Auer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4808-8852","authenticated-orcid":false,"given":"Kathrin","family":"Klar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4480-9351","authenticated-orcid":false,"given":"Eugen","family":"Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,11]]},"reference":[{"key":"8305_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17670-y","volume":"11","author":"C Robert","year":"2020","unstructured":"Robert, C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat. Commun. 11, 3801 (2020).","journal-title":"Nat. Commun."},{"key":"8305_CR2","doi-asserted-by":"publisher","first-page":"2308097","DOI":"10.1080\/15384047.2024.2308097","volume":"25","author":"GS Santiago-S\u00e1nchez","year":"2024","unstructured":"Santiago-S\u00e1nchez, G. S., Fabian, K. P. & Hodge, J. W. A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance. Cancer Biol. Ther. 25, 2308097 (2024).","journal-title":"Cancer Biol. Ther."},{"key":"8305_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39817-3","volume":"14","author":"M Haake","year":"2023","unstructured":"Haake, M. et al. Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment. Nat. Commun. 14, 4253 (2023).","journal-title":"Nat. Commun."},{"key":"8305_CR4","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","volume":"50","author":"E Batlle","year":"2019","unstructured":"Batlle, E. & Massagu\u00e9, J. Transforming growth factor-\u03b2 signaling in immunity and cancer. Immunity. 50, 924\u2013940 (2019).","journal-title":"Immunity."},{"key":"8305_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.semcdb.2019.12.010","volume":"101","author":"M Lodyga","year":"2020","unstructured":"Lodyga, M. & Hinz, B. TGF-\u03b21 - a truly transforming growth factor in fibrosis and immunity. Semin. Cell Dev. Biol. 101, 123\u2013139 (2020).","journal-title":"Semin. Cell Dev. Biol."},{"key":"8305_CR6","doi-asserted-by":"publisher","first-page":"951","DOI":"10.3389\/fimmu.2020.00951","volume":"11","author":"J Wischhusen","year":"2020","unstructured":"Wischhusen, J., Melero, I. & Fridman, W. H. Growth\/differentiation factor-15 (GDF-15): from biomarker to novel targetable immune checkpoint. Front. Immunol. 11, 951 (2020).","journal-title":"Front. Immunol."},{"key":"8305_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0140-6736(03)15265-8","volume":"363","author":"S Tong","year":"2004","unstructured":"Tong, S. et al. Serum concentrations of macrophage inhibitory cytokine 1 (MIC 1) as a predictor of miscarriage. Lancet 363, 129\u2013130 (2004).","journal-title":"Lancet"},{"key":"8305_CR8","doi-asserted-by":"publisher","first-page":"e72437","DOI":"10.1371\/journal.pone.0072437","volume":"8","author":"TJ Kaitu\u2019u-Lino","year":"2013","unstructured":"Kaitu\u2019u-Lino, T. J. et al. Plasma MIC-1 and PAPP-a levels are decreased among women presenting to an early pregnancy assessment unit, have fetal viability confirmed but later miscarry. PLoS ONE 8, e72437 (2013).","journal-title":"PLoS ONE"},{"key":"8305_CR9","first-page":"1121","volume":"11","author":"A Delgado","year":"2021","unstructured":"Delgado, A. & Guddati, A. K. Clinical endpoints in oncology - a primer. Am. J. Cancer Res. 11, 1121\u20131131 (2021).","journal-title":"Am. J. Cancer Res."},{"key":"8305_CR10","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1007\/s11357-021-00359-5","volume":"43","author":"J Tavenier","year":"2021","unstructured":"Tavenier, J. et al. Longitudinal course of GDF15 levels before acute hospitalization and death in the general population. Geroscience 43, 1835\u20131849 (2021).","journal-title":"Geroscience"},{"key":"8305_CR11","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.21873\/anticanres.13543","volume":"39","author":"K Fujita","year":"2019","unstructured":"Fujita, K. et al. Retreatment with anti-PD-L1 antibody in advanced non-small cell lung cancer previously treated with anti-PD-1 antibodies. Anticancer Res. 39, 3917\u20133921 (2019).","journal-title":"Anticancer Res."},{"key":"8305_CR12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/1759-7714.13241","volume":"11","author":"K Fujita","year":"2020","unstructured":"Fujita, K. et al. Retreatment with anti-PD-1 antibody in non-small cell lung cancer patients previously treated with anti-PD-L1 antibody. Thorac. Cancer 11, 15\u201318 (2020).","journal-title":"Thorac. Cancer"},{"key":"8305_CR13","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/jjco\/hyz066","volume":"49","author":"H Watanabe","year":"2019","unstructured":"Watanabe, H. et al. The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer. Jpn. J. Clin. Oncol. 49, 762\u2013765 (2019).","journal-title":"Jpn. J. Clin. Oncol."},{"key":"8305_CR14","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3390\/jcm9010102","volume":"9","author":"Y Katayama","year":"2019","unstructured":"Katayama, Y. et al. Retrospective efficacy analysis of immune checkpoint inhibitor rechallenge in patients with non-small cell lung cancer. J. Clin. Med. 9, 102 (2019).","journal-title":"J. Clin. Med."},{"key":"8305_CR15","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s00280-018-3585-9","volume":"81","author":"K Fujita","year":"2018","unstructured":"Fujita, K. et al. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases. Cancer Chemother. Pharmacol. 81, 1105\u20131109 (2018).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"8305_CR16","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.clgc.2022.11.003","volume":"21","author":"D Makrakis","year":"2023","unstructured":"Makrakis, D. et al. Treatment rechallenge with immune checkpoint inhibitors in advanced urothelial carcinoma. Clin. Genitourin. Cancer 21, 286\u2013294 (2023).","journal-title":"Clin. Genitourin. Cancer"},{"key":"8305_CR17","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.2217\/fon-2021-0230","volume":"17","author":"D Stenehjem","year":"2021","unstructured":"Stenehjem, D. et al. Treatment patterns in patients with metastatic non-small-cell lung cancer in the era of immunotherapy. Future Oncol. 17, 2940\u20132949 (2021).","journal-title":"Future Oncol."},{"key":"8305_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-58674-4","volume":"10","author":"L Sun","year":"2020","unstructured":"Sun, L. et al. Clinical efficacy and safety of anti-PD-1\/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis. Sci. Rep. 10, 2083 (2020).","journal-title":"Sci. Rep."},{"key":"8305_CR19","doi-asserted-by":"publisher","first-page":"1192762","DOI":"10.3389\/fmed.2023.1192762","volume":"10","author":"TS Fitzsimmons","year":"2023","unstructured":"Fitzsimmons, T. S. et al. Immune checkpoint inhibitors efficacy across solid cancers and the utility of PD-L1 as a biomarker of response: a systematic review and meta-analysis. Front. Med. 10, 1192762 (2023).","journal-title":"Front. Med."},{"key":"8305_CR20","doi-asserted-by":"publisher","unstructured":"Long, G. V. et al. Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: results of the phase 3 ECHO-301\/KEYNOTE-252 study. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.108 (2018).","DOI":"10.1200\/JCO.2018.36.15_suppl.108"},{"key":"8305_CR21","doi-asserted-by":"publisher","first-page":"S868","DOI":"10.1016\/j.annonc.2021.08.1422","volume":"32","author":"A Ribas","year":"2021","unstructured":"Ribas, A. et al. MASTERKEY-265: a phase III, randomized, placebo (Pbo) controlled study of talimogene laherparepvec (T)plus pembrolizumab (P) for unresectable stage IIIB\u2013IVM1c melanoma (MEL). Ann. Oncol. 32, S868\u2013S869 (2021).","journal-title":"Ann. Oncol."},{"key":"8305_CR22","doi-asserted-by":"publisher","first-page":"4756","DOI":"10.1200\/JCO.23.00172","volume":"41","author":"A Diab","year":"2023","unstructured":"Diab, A. et al. Bempegaldesleukin plus nivolumab in untreated advanced melanoma: the open-label, phase III PIVOT IO 001 trial results. J. Clin. Oncol. 41, 4756\u20134767 (2023).","journal-title":"J. Clin. Oncol."},{"key":"8305_CR23","doi-asserted-by":"publisher","first-page":"11514","DOI":"10.1073\/pnas.94.21.11514","volume":"94","author":"MR Bootcov","year":"1997","unstructured":"Bootcov, M. R. et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc. Natl Acad. Sci. USA 94, 11514\u201311519 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"8305_CR24","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.cmet.2019.12.004","volume":"31","author":"T Borner","year":"2020","unstructured":"Borner, T. et al. GDF15 induces anorexia through nausea and emesis. Cell Metab. 31, 351\u2013362 (2020).","journal-title":"Cell Metab."},{"key":"8305_CR25","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.cmet.2020.10.023","volume":"32","author":"DM Breen","year":"2020","unstructured":"Breen, D. M. et al. GDF-15 neutralization alleviates platinum-based chemotherapy-induced emesis, anorexia, and weight loss in mice and nonhuman primates. Cell Metab. 32, 938\u2013950 (2020).","journal-title":"Cell Metab."},{"key":"8305_CR26","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.1073\/pnas.0530278100","volume":"100","author":"JB Welsh","year":"2003","unstructured":"Welsh, J. B. et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc. Natl Acad. Sci. USA 100, 3410\u20133415 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"8305_CR27","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1172\/JCI91561","volume":"127","author":"NM Ratnam","year":"2017","unstructured":"Ratnam, N. M. et al. NF-\u03baB regulates GDF-15 to suppress macrophage surveillance during early tumor development. J. Clin. Invest. 127, 3796\u20133809 (2017).","journal-title":"J. Clin. Invest."},{"key":"8305_CR28","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s42255-021-00366-y","volume":"3","author":"JH Weng","year":"2021","unstructured":"Weng, J. H. et al. Colchicine acts selectively in the liver to induce hepatokines that inhibit myeloid cell activation. Nat. Metab. 3, 513\u2013522 (2021).","journal-title":"Nat. Metab."},{"key":"8305_CR29","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1158\/2326-6066.CIR-14-0161","volume":"2","author":"ML Dustin","year":"2014","unstructured":"Dustin, M. L. The immunological synapse. Cancer Immunol. Res. 2, 1023\u20131033 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"8305_CR30","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3390\/cells8050463","volume":"8","author":"H Wurzer","year":"2019","unstructured":"Wurzer, H. et al. Actin cytoskeleton straddling the immunological synapse between cytotoxic lymphocytes and cancer cells. Cells. 8, 463 (2019).","journal-title":"Cells."},{"key":"8305_CR31","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1038\/nm.4394","volume":"23","author":"L Yang","year":"2017","unstructured":"Yang, L. et al. GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand. Nat. Med. 23, 1158\u20131166 (2017).","journal-title":"Nat. Med."},{"key":"8305_CR32","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1158\/1078-0432.CCR-23-1631","volume":"30","author":"J Crawford","year":"2024","unstructured":"Crawford, J. et al. A phase Ib first-in-patient study assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of ponsegromab in participants with cancer and cachexia. Clin. Cancer Res. 30, 489\u2013497 (2024).","journal-title":"Clin. Cancer Res."},{"key":"8305_CR33","doi-asserted-by":"publisher","first-page":"abstr. CT100","DOI":"10.1158\/1538-7445.AM2024-CT100","volume":"84","author":"BA Carneiro","year":"2024","unstructured":"Carneiro, B. A. et al. Safety and efficacy of AZD8853, an anti-growth and differentiation factor 15 (GDF15) antibody, in patients (pts) with advanced\/metastatic solid tumors: first-in-human study. Cancer Res. 84, abstr. CT100 (2024).","journal-title":"Cancer Res."},{"key":"8305_CR34","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/j.ccell.2023.08.004","volume":"41","author":"BG Topp","year":"2023","unstructured":"Topp, B. G. et al. Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression. Cancer Cell 41, 1680\u20131688 (2023).","journal-title":"Cancer Cell"},{"key":"8305_CR35","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst, R. S. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387, 1540\u20131550 (2016).","journal-title":"Lancet"},{"key":"8305_CR36","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","volume":"18","author":"P Sharma","year":"2017","unstructured":"Sharma, P. et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 18, 312\u2013322 (2017).","journal-title":"Lancet Oncol."},{"key":"8305_CR37","doi-asserted-by":"publisher","first-page":"e002787","DOI":"10.1136\/jitc-2021-002787","volume":"9","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. GDF15 induces immunosuppression via CD48 on regulatory T cells in hepatocellular carcinoma. J. Immunother. Cancer 9, e002787 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"8305_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0638-6","volume":"11","author":"F Finotello","year":"2019","unstructured":"Finotello, F. et al. Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Med. 11, 34 (2019).","journal-title":"Genome Med."},{"key":"8305_CR39","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41576-019-0166-7","volume":"20","author":"F Finotello","year":"2019","unstructured":"Finotello, F. et al. Next-generation computational tools for interrogating cancer immunity. Nat. Rev. Genet. 20, 724\u2013746 (2019).","journal-title":"Nat. Rev. Genet."},{"key":"8305_CR40","doi-asserted-by":"publisher","first-page":"i436","DOI":"10.1093\/bioinformatics\/btz363","volume":"35","author":"G Sturm","year":"2019","unstructured":"Sturm, G. et al. Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology. Bioinformatics. 35, i436\u2013i445 (2019).","journal-title":"Bioinformatics."},{"key":"8305_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara, K. et al. Inferring tumour purity and stromal and immune cell admixture from 884 expression data. Nat. Commun. 4, 2612 (2013).","journal-title":"Nat. Commun."},{"key":"8305_CR42","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/s41379-020-0644-7","volume":"34","author":"EJ De Ruiter","year":"2021","unstructured":"De Ruiter, E. J. et al. Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC). Mod. Pathol. 34, 1125\u20131132 (2021).","journal-title":"Mod. Pathol."},{"key":"8305_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-03949-3","volume":"21","author":"FJ Koll","year":"2023","unstructured":"Koll, F. J. et al. Tumor-associated macrophages and Tregs influence and represent immune cell 889 infiltration of muscle-invasive bladder cancer and predict prognosis. J. Transl. Med. 21, 124 (2023).","journal-title":"J. Transl. Med."},{"key":"8305_CR44","doi-asserted-by":"publisher","unstructured":"Hubert, H., Falk, G. & Zlatko, T. Association of GDF-15 expression with immune parameter in a pan-cancer analysis. Zenodo https:\/\/doi.org\/10.5281\/zenodo.13716226 (2024).","DOI":"10.5281\/zenodo.13716226"}],"updated-by":[{"DOI":"10.1038\/s41586-025-08827-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000}}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-024-08305-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-024-08305-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-024-08305-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T00:41:52Z","timestamp":1743295312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-024-08305-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,11]]},"references-count":44,"journal-issue":{"issue":"8048","published-print":{"date-parts":[[2025,1,30]]}},"alternative-id":["8305"],"URL":"https:\/\/doi.org\/10.1038\/s41586-024-08305-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4003985\/v1","asserted-by":"object"}]},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,11]]},"assertion":[{"value":"1 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41586-025-08827-0","URL":"https:\/\/doi.org\/10.1038\/s41586-025-08827-0","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.H. and J.W. are co-founders and stock owners of CatalYm. A.d.S., M.\u2009R\u00fcdiger, P.L\u2019H., M.H., J.A., A.D., A.A., A.G., F.H., M.A., M.L., D.R., C.S.-W., F.S.L., P.F., K.K., F.H., B.R. and E.L. are current or former employees of and\/or hold stock options in Catalym. R.D., M.H., J.W., K.K., E.L., F.H., M.\u2009R\u00fcdiger and C.S.-W. are inventors on patents related to visugromab and anti-GDF-15 treatment (WO2014049087, WO2015144855, WO2017055613, WO2022101263, WO2024052532, WO2024126808 and unpublished). I.\u2009Melero, H.H., R.B., R.D., J.W., F.J.K., A.M.M.E., W.H.F., T.F.G., P.L., M.M., S.S., A.T. and J.R. have received research funding or consulting or advisory fees from CatalYm. Several authors and investigators declare potentially competing interests (grants or contracts and\/or royalties or licences, stock or stock options, consulting fees, honoria, travel or meeting support, or advisory or data safety monitoring board participation) apart from their relationship with CatalYm: I. Melero (Agenus, Alligator, Allmiral, AstraZeneca, Biontech, BMS, Boehringer Ingelheim, Bright Peak, Crescendo Biologics, Curon, Dynamicure, F-Star, Genmab, Highlight Therapeutics, HotSpot, Merck Serono, MSD, Merus, Mestag, Numab, PharmaMar, Pieris, Pierre Fabre, Pioneering Medicines, Roche, Sanofi and Servier); G.d.V. (Astellas, AstraZeneca, Bayer, BMS, Ipsen, Janssen MSD, Merck Serono, Pfizer and Roche); E.G. (Anaveon, BeiGene, Boehringer Ingelheim, Ellipses Pharma, F-Star Therapeutics, Hengrui, Incyte, Janssen Global Services, MabDiscovery, Medscape, MSD, Novartis, Seattle Genetics, Sanofi, Roche, SeaGen, Taiho and Thermo Fisher); J.M.-L. (Astellas, BMS, Highlight Therapeutics, Merck Serono, MSD, Novartis, Ipsen, Roche, Sanofi and Pierre Fabre); M.J. (Adoram, AstraZeneca, Debiopharm, Novartis, Roche, Sanofi and Takeda); M.-E.G. (BMS, Janssen, Novartis and Roche); M.S. (Amgen, AstraZeneca, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Janssen, MSD, Novartis, Roche, Sanofi and Tacalyx); D.K. (AstraZeneca, Amgen, BMS, Merck Serono, MSD, Mirati, PharmaMar, Sanofi and Swiss Oncology in Motion); R.D. (Alligator, Amgen, BMS, MSD, Novartis, Pierre Fabre, Roche, Sun Pharma, Takeda, Sanofi, Second-Genome, Regeneron, T3 Pharma, MaviVax, Pfizer, Simcere and touchIME); M. Reig (AstraZeneca, Bayer, BMS, Boston Scientific, Biotoscana Pharma, Engitix Therapeutics, Eli Lilly, Geneos, Gilead, Ipsen, Merck, Roche and Universal DC); M.-E.R.R. (BMS, Imcore-Roche, Roche and Highlight Therapeutics); E.C. (Achilles, Adcendo, Alkermes, Amunix, Anaveon, Amcure, AstraZeneca, BeiGene, BMS, Boehringer, Chugai, Debiopharm, Diaccurate, Ellipses, Incyte, iTeos, Janssen, Merus, MonTa, MSD, Nanobiotix, Nouscom, Novartis, OncoDNA, PharmaMar, PsiOxus Therapeutics, Roche\/Genentech, Sanofi, Servier, Shionogi, Syneos Health, TargImmune, T-knife and Tolremo); J.E.-V. (BMS, MSD and Pfizer); J.J.S.-C. (Eisai, Novartis, Pfizer and Seagen); K.-L.K. (Janssen and Takeda); O.S. (Affimed); C.S. (BMS, Eli Lilly and Boehringer Ingelheim); E.R. (BMS, Eli Lilly, Kyowa Kirin, Leo Pharma, MSD, Pierre Fabre and Sanofi); A.L.-M. (Incyte, Merck, PharmaMar, Pfizer, Roche, Rovi and Sanofi); I. Moreno (Digicore Initiative, Fondacion Intheos, Exafield, Guidepoint and Ellipses Pharma); A.H.-C. (BMS, Gilead, Kyowa Kirin, Merus and MSD); D.H. (Novartis and Roche); M.S.-Z. (Bayer, Instituto de Salud Carlos III (grant FI19\/00222), BTG, MSD and Roche); A.V.-L. (AstraZeneca, BMS, Health in Code and Roche); J.T. (Amgen, AstraZeneca, Bristol Myers Squibb, Eisai, EXACT Therapeutics, Institut f\u00fcr Qualit\u00e4tssicherung und Transparenz im Gesundheitswesen, Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen, Ipsen, Lilly ImClone, medupdate, Merck Serono, Merck Sharp & Dome, Oncolytics Biotech, onkowissen.de, Roche, Servier and streamedup!); C.K. (AstraZenca, BMS, DGVS, Incyte, MCI Deutschland, MSD, Servier, Ipsen, Merck Serono and Roche); P.R.G. (AstraZeneca, Bayer, BMS, Boston Scientific, Eisai, Guerbet, Ipsen, MSD, Lilly, Roche and Sirtex); F.F. (AstraZeneca, BMS, Eisai, Merck Serono, Servier and Roche); Z.T. (Boehringer Ingelheim); H.H. (Secarna); F.J.K. (German Cancer Aid (Deutsche Krebshilfe)); H. Reis (AstraZeneca, BMS, Boehringer Ingelheim, Chop GmbH, Diaceutics, GSK, HUeG, Janssen, MCI, Merck, Novartis, Roche Pharma and Sanofi); M.M. (LYO-X AG and TATAA Biocenter); T.G. (Allogene, Bicara, BMS, Merck, Pyxis and Samyang); W.H.F. (Anaveon, Atreca, Incendia, Ichnos Sciences, Genenta, OSE Immunotherapeutics, Oxford Biotherapeutics, Mestag, Novartis, Roche and Tabby); A.M.M.E. (Acetra, Agenus, BMS, Boehringer Ingelheim, BioInvent, BioNTech, Ellipses, Galecto, GSK, IO Biotech, IQVIA, Isa Pharmaceuticals, Merck & Co, MSD, Pfizer, Pierre Fabre, Sairopa, Sellas, SkylineDX, TigaTx and Trained Immunity); R.B. (Amgen, Avencell); J.R. (Astellas, AstraZeneca, BMS, Daiichi Sankyo, GSK, MSD, Merck and Sanofi); F.H. (Thermosome); P.F. (Curevac); J.W. (Bayrische Forschungsstiftung (FORTiTher) and the German Ministry for Education & Research (Transcan-3)). The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}